Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer.
作者信息
Neoptolemos John P, Ghaneh Paula, Hackert Thilo
机构信息
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Department of Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK.
出版信息
Hepatobiliary Surg Nutr. 2021 Oct;10(5):714-716. doi: 10.21037/hbsn-21-131.
Abstract
摘要
相似文献
1
Multimodality standard of care treatment of resectable and borderline resectable pancreatic cancer.可切除及临界可切除胰腺癌的多模式标准治疗护理
Hepatobiliary Surg Nutr. 2021 Oct;10(5):714-716. doi: 10.21037/hbsn-21-131.
2
Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience.“可切除边缘”胰腺神经内分泌肿瘤的多模态管理：单机构经验报告
Cancer Control. 2017 Oct-Dec;24(5):1073274817729076. doi: 10.1177/1073274817729076.
3
The past, present, and future status of multimodality treatment for resectable/borderline resectable pancreatic ductal adenocarcinoma.可切除/交界可切除胰腺导管腺癌的多模态治疗的过去、现在和未来状况。
Surg Today. 2020 Apr;50(4):335-343. doi: 10.1007/s00595-020-01963-2. Epub 2020 Jan 28.
4
Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis.新辅助治疗与直接手术治疗在可切除和临界可切除胰腺导管腺癌中的疗效比较：荟萃分析
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zrae172.
5
Outcomes of Patients with Borderline Resectable Pancreatic Cancer Treated with Combination Chemotherapy.伴可切除边缘性胰腺癌患者接受联合化疗的治疗结果。
J Gastrointest Cancer. 2021 Jun;52(2):529-535. doi: 10.1007/s12029-020-00417-9.
6
[Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer].[可切除或交界可切除胰腺癌的新辅助治疗]
Korean J Gastroenterol. 2024 Sep 25;84(3):103-110. doi: 10.4166/kjg.2024.079.
7
Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.可切除交界性胰腺癌患者接受新辅助治疗和手术的生存情况。
Surgery. 2019 Sep;166(3):277-285. doi: 10.1016/j.surg.2019.05.010. Epub 2019 Jul 2.
8
Resectable, borderline, and locally advanced pancreatic cancer-"the good, the bad, and the ugly" candidates for surgery?可切除、临界可切除及局部进展期胰腺癌——手术的“好人、坏人、丑人”候选者？
J Gastrointest Oncol. 2021 Oct;12(5):2450-2460. doi: 10.21037/jgo-2020-slapc-04.
9
Implementation of a standardized approach to borderline resectable pancreatic cancer in a multisite community oncology program.在多中心社区肿瘤项目中实施针对可切除边缘性胰腺癌的标准化方法。
Surg Open Sci. 2020 Jul 29;2(4):25-31. doi: 10.1016/j.sopen.2020.07.003. eCollection 2020 Oct.
10
Diagnosis and Management of Borderline Resectable Pancreatic Adenocarcinoma.可切除边缘性胰腺癌的诊断与管理
Hematol Oncol Clin North Am. 2015 Aug;29(4):727-40. doi: 10.1016/j.hoc.2015.04.004. Epub 2015 Jun 9.
引用本文的文献
1
Potential role of the bitter taste receptor T2R14 in the prolonged survival and enhanced chemoresponsiveness induced by apigenin.柚皮素诱导的延长生存时间和增强化疗反应的潜在作用机制：苦味受体 T2R14 的作用。
Int J Oncol. 2023 Jan;62(1). doi: 10.3892/ijo.2022.5454. Epub 2022 Nov 16.
2
Quantitative definitions of prognostic indicators of resectable pancreatic cancer.可切除胰腺癌预后指标的定量定义。
Gland Surg. 2022 Sep;11(9):1584-1585. doi: 10.21037/gs-22-354.
3
The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"?全身治疗时代胰腺癌的管理策略——“手术优先”还是“手术最后”？
Hepatobiliary Surg Nutr. 2022 Aug;11(4):597-600. doi: 10.21037/hbsn-22-146.
本文引用的文献
1
Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas.联盟 A021501 的放射治疗质量保证分析：术前 mFOLFIRINOX 或 mFOLFIRINOX 联合低分割放射治疗局部可切除胰腺腺癌。
Int J Radiat Oncol Biol Phys. 2024 Sep 1;120(1):111-119. doi: 10.1016/j.ijrobp.2024.03.013. Epub 2024 Mar 15.
2
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.可切除胰腺腺癌围手术期化疗的疗效：一项 2 期随机临床试验。
JAMA Oncol. 2021 Mar 1;7(3):421-427. doi: 10.1001/jamaoncol.2020.7328.
3
Systemic therapy without radiation may be appropriate as neoadjuvant therapy for localized pancreas cancer.对于局限性胰腺癌，不进行放疗的全身治疗可能适合作为新辅助治疗。
Hepatobiliary Surg Nutr. 2020 Jun;9(3):296-303. doi: 10.21037/hbsn.2019.04.17.
4
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer.FOLFIRINOX 或吉西他滨作为胰腺癌的辅助治疗。
N Engl J Med. 2018 Dec 20;379(25):2395-2406. doi: 10.1056/NEJMoa1809775.
5
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial.比较吉西他滨和卡培他滨辅助治疗与吉西他滨单药治疗可切除胰腺癌患者的效果（ESPAC-4）：一项多中心、开放标签、随机、3 期临床试验。
Lancet. 2017 Mar 11;389(10073):1011-1024. doi: 10.1016/S0140-6736(16)32409-6. Epub 2017 Jan 25.
6
A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.胰腺癌切除术后放化疗与单纯化疗的随机试验。
N Engl J Med. 2004 Mar 18;350(12):1200-10. doi: 10.1056/NEJMoa032295.
Zotero 插件